Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
109 results about "Acquired immunodeficiency" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Acquired Immunodeficiency Syndrome (AIDS) A disease of the immune system due to infection with HIV. ... Acquired immunodeficiency syndrome (AIDS) is the most advanced stage of HIV infection. To be diagnosed with AIDS, a person with HIV must have an AIDS-defining condition or have a CD4 count less than 200 cells/mm 3 (regardless of whether the person has an AIDS-defining condition).
Nitrogenated heterocyclic derivative , and pharmaceutical agent comprising the derivative as active ingredient
InactiveUS20090131403A1Prevention and/or treatmentEasy to useBiocideSenses disorderAcquired immunodeficiencyAutoimmune condition
The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and / or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so on.Wherein all symbols in formula are as defined in the specification
Owner:ONO PHARMA CO LTD
APJ ligand polypeptides
InactiveUS6492324B1Lower Level RequirementsImprove the level ofBiocidePeptide/protein ingredientsAcquired immunodeficiencyReproductive function
Owner:TAKEDA PHARMA CO LTD
Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome
InactiveUS6039684AGood conditionPromote resultsPeptide/protein ingredientsEnergy modified materialsAcquired immunodeficiencyImmunodeficiency virus
The present invention relates to the use of a non-lethal preparative regimen for the treatment of a patient with human immunodeficiency virus (HIV) disease. In a clinical trial, an HIV-positive patient was conditioned by non-lethal doses of irradiation and a chemotherapeutic drug prior to receiving donor bone marrow cells from a baboon. While long-term engraftment of donor cells was not observed, the non-lethal preparative conditioning regimen was able to reduce the viral burden and improved the clinical outcome. Such method is useful for treatment of patients with advanced acquired immunodeficiency syndrome (AIDS).
Owner:ALLEGHENY UNIV OF THE HEALTH SCI +1
Non-lethal methods for conditioning a recipient for bone marrow transplantation
InactiveUS6217867B1Reduce proliferationDiminished cytotoxic activityBiocideOrganic active ingredientsGackstroemiaAcquired immunodeficiency
The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.
Owner:PITTSBURGH UNIV OF
Flt3 inhibitors for immune suppression
InactiveUS20090054358A1Suppressing response of cellReduce in quantityBiocideNervous disorderAcquired immunodeficiencySystemic lupus erythematosus
New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Reduction in bacterial colonization by administering bacteriophage compositions
InactiveUS7459272B2Reduce and eliminate colonizationReduce riskAntibacterial agentsBiocideBacteroidesAcquired immunodeficiency
The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.
Owner:INTRALYTIX
Novel antiviral pyrrolopyridine derivatives and method for preparing the same
ActiveUS20140249162A1Strong antiviral activityHigh selectivityBiocideOrganic chemistryAcquired immunodeficiencyWild type
The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).
Owner:ST PHARM
Antigenic composition comprising an HIV gag or env polypeptide
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC +1
Non-lethal methods for conditioning a recipient for bone marrow transplantation
InactiveUS20030165475A1Diminished proliferative and cytotoxic activityDosage of TBI can be further reducedBiocideEnergy modified materialsAcquired immunodeficiencyGackstroemia
The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.
Owner:ILDSTAD SUZANNE T
HIV immunoassays using synthetic envelope polypeptides
ActiveUS7273695B1Peptide/protein ingredientsAntibody mimetics/scaffoldsAntigenAcquired immunodeficiency
Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and / or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC +1
Human immunodeficiency virus (HIV) nucleotide sequences
Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and / or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC
Basic group-containing compound and use thereof
A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac / vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.
Owner:ONO PHARMA
Compounds for modulating integrin CD11b/CD18
ActiveUS20100056503A1More selective and potentBiocideOrganic chemistryAcquired immunodeficiencyReperfusion injury
The application describes an assay for the identification of small molecule modulators of integrin CD11b / CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
Owner:THE GENERAL HOSPITAL CORP
Highly effective method for amplifying activated lymphocyte and cultivation system
ActiveCN101302491AAvoid damageLow costMammal material medical ingredientsBlood/immune system cellsAbnormal tissue growthAcquired immunodeficiency
The invention relates to a method for expanding activated lymphocyte, comprising the steps of allowing biologic sample containing lymphocytes to contact immobilized anti-CD 3 antibodies, then cultivating activated lymphocytes with culture mediums in different IL-2 concentrations to expand the activated lymphocytes. The invention also relates to a cultivation system used for expanding activated lymphocytes. The expanded activated lymphocytes can be applied in the immunotherapy of tumor, infectious diseases, and congenital or acquired immunodeficiency diseases.
Owner:BEIJING YONGTAI IMMUNITY APPL TECH
Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
InactiveUS6869759B1Identification and of fitnessSugar derivativesMicrobiological testing/measurementAcquired immunodeficiencyImmunodeficiency virus
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.
Owner:MONOGRAM BIOSCIENCES
Gastrodia elata polypeptide, preparation method and medical application of gastrodia elata polypeptide in antibiosis and antiviral
ActiveCN105087732ADefinite curative effectImprove stabilityAntibacterial agentsAntimycoticsAcquired immunodeficiencyUltrafiltration
The invention provides gastrodia elata polypeptide, a preparation method and medical application of the gastrodia elata polypeptide in antibiosis and antiviral. Gastrodia elata protein is extracted, filtered and concentrated, is subjected to enzymolysis, ultrafiltration and separation, is mixed with suitable auxiliary materials according to use and application fields in proportion, and then is prepared into corresponding preparations. The gastrodia elata polypeptide is a product obtained from natural resources, and even a small amount of gastrodia elata polypeptide (10-7mol / L) has obvious biological activity. An experiment proves that the gastrodia elata polypeptide has excellent antibiosis and antiviral capabilities, has quite high killability on common pathogenic bacteria and viruses, also has the advantages of zero hemolytic activity and zero plasma coagulation activity, and can be used for preparing medicines which have an antibiosis function and can resist viral influenza, viral hepatitis, influenzavirus A sous-type H1N1, coronavirus and human acquired immunodeficiency viruses.
Owner:通化仁生源生物科技股份有限公司
Polypeptides, their production and use
InactiveUS20030092618A1Nervous disorderPeptide/protein ingredientsAcquired immunodeficiencyReproductive function
This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.
Owner:TAKEDA PHARMA CO LTD
Nucleobase phosphonate analogs for antiviral treatment
ActiveUS20050059637A1Increasing cellular accumulationImprove retentionBiocideOrganic active ingredientsHigh concentrationAcquired immunodeficiency
The present invention provides novel compounds with activity against infectious viruses. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and / or related diseases. The present invention also relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of active metabolite molecules in HIV infected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.
Owner:GILEAD SCI INC
Compound having spiro-bonded cyclic group and use thereof
InactiveUS20120101280A1High antagonistic activityReduce riskBiocideSenses disorderVery low riskAcquired immunodeficiency
The invention relates to a compound represented by formula (I):a salt thereof, an N-oxide thereof, or a solvate thereof (symbols in the formula are as described in the specification).The compound of the present invention exhibits very low risk of side effects and also has persistent and strong antagonistic activity against CXCR4, and is therefore useful as pharmaceuticals, for example, preventive and / or therapeutic agent for inflammatory and immune diseases, infections (for example, HIV infection), diseases associated with HIV infection (for example, acquired immunodeficiency syndrome (AIDS)), cancer, cancer metastasis, psychoneurotic diseases and cardiovascular diseases (for example, retinopathy), metabolic diseases, cancerous diseases, or an agent for regeneration therapy.
Owner:ONO PHARMA CO LTD
Heterocyclic compound containing nitrogen atom and use thereof
InactiveUS20070043079A1Promote oral absorptionAvoid problemsAntibacterial agentsBiocideAcquired immunodeficiencyAutoimmune condition
The present invention relates to a medicament comprising the compound of formula (I) wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and / or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or HIV infections (e.g. asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), organ transplantation rejection, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection (acquired immunodeficiency syndrome etc.), atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacteria infection, diabetes, cancer metastasis, atherosclerosis, etc.).
Owner:ONO PHARMA CO LTD
3-nitropyridine derivaives and the pharmaceutical compositions containing said derivatives
InactiveUS6743795B1Effective preventionEffective treatmentOrganic active ingredientsOrganic chemistryImmunodeficiency virusHepatitis B virus
The present invention relates to novel 3-nitropyridine derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same as active ingredients. Methods of preparing the derivatives and pharmaceutical compositions containing the same are also disclosed. The 3-nitropyridine derivatives of the present invention, due to their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV), can be used as therapeutic agents as well as preventive agents for hepatitis B and acquired immune deficiency syndrome (AIDS).
Owner:DONG WHA PHARM CO LTD
Novel urea and thiourea derivatives
The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O)2—, —C(═S)— and P(═O)(R5)—; B is, —O—, —(CH2)3-6—, and O—(CH2)2-5—; D is, —O—, —CR7R8— and —NR9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R1 is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.
Owner:ONXEO DK BRANCH OF ONXEO S A FRANCE
Compounds and methods of use to treat infectious diseases
The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.
Owner:FERRING BV
Modified venom and venom components as anti-retroviral agents
InactiveUS20060088858A1Avoid infectionInhibition of replicationPeptide/protein ingredientsMicrobiological testing/measurementFeline immunodeficiency virusAcquired immunodeficiency
The present invention relates to a class of proteins, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified modified venom composition.
Owner:RECEPTOPHARM
Modified venom and venom components as anti-retroviral agents
InactiveUS20050255097A1Strong antiviral activityAvoid infectionBiocideNervous disorderFeline immunodeficiency virusAcquired immunodeficiency
The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The
Owner:RECEPTOPHARM
Natural Pharmaceutical Preparations for Increasing Albumin
InactiveUS20110033556A1Eliminate side effectsDelay drug resistanceAntibacterial agentsBiocideHypoproteinemiaAcquired immunodeficiency
A natural pharmaceutical preparation for treating hypoproteinemia, includes at least one member selected from the group consisting of a drug of increasing human serum albium, a drug of improving and enhance immunity, a drug of treating hepatitis B, a drug of treating Hepatitis C, a drug of treating acquired immune deficiency syndrome (AIDS), a drug of treating Tuberculosis, a drug of treat Fibrosis, a drug of treating hydrothorax, a drug of easing pain, a drug of stopping diarrhea, a drug of arresting coughing, a drug of reducing inflammation, and a drug of increasing urine.
Owner:JIN ZHEMING +1
Compound having cyclic group bound thereto through spiro binding and use thereof
InactiveUS20090325992A1Prevention and therapyTreatment safetyAntibacterial agentsBiocideDiseaseMental nerve
A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.
Owner:ONO PHARMA CO LTD
Modified venom and venom components as anti-retroviral agents
InactiveUS20060088843A1Strong antiviral activityAvoid infectionPeptide/protein ingredientsMicrobiological testing/measurementFeline immunodeficiency virusAcoleareine
The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified and neurotropically active modified venom composition containing alpha-neurotoxins that target a nicotinic acetylcholine receptor.
Owner:RECEPTOPHARM
Compounds for modulating integrin CD11b/CD18
The application describes an assay for the identification of small molecule modulators of integrin CD11b / CD18 and small molecules capable of modulating activity of this receptor. For example, one such compound useful as an agonist of integrin CD11b / CD18 is the compound of Formula (I):Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
Owner:THE GENERAL HOSPITAL CORP
Method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of interstitial cystitis treatment; method of acquired immune deficiency syndrome treatment; and method of herpes treatment
InactiveUS20060062762A1Strengthen the patient's immune systemPromote regenerationBiocidePeptide/protein ingredientsAcquired immunodeficiencyInterstitial cystitis
A method treating diseases including cancer comprising administering a drug which provides interferon alpha once inside the body, administering a vaccine containing tumor necrosis factor, and administering a predetermined quantity of an anti-viral drug. The three drugs work together to strengthen the patient's immune system, make the infection or virus more vulnerable to attack by the immune system, and enabling the body to regenerate healthy cells and tissues damaged by the infection or disease. The foregoing treatment method is also effective in treating Type I diabetes, obesity, multiple sclerosis, interstitial cystitis, acquired immune deficiency syndrome, herpes simplex, and herpes zoster.
Owner:LES MEDECINS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com